Log in

NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

$12.12
-2.48 (-16.99 %)
(As of 02/26/2020 07:23 AM ET)
Today's Range
$11.80
Now: $12.12
$14.64
50-Day Range
$12.12
MA: $13.90
$16.09
52-Week Range
$10.91
Now: $12.12
$25.84
Volume926,561 shs
Average Volume263,390 shs
Market Capitalization$478.38 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$106.71 million
Book Value$3.84 per share

Profitability

Net Income$-22,400,000.00

Miscellaneous

EmployeesN/A
Market Cap$478.38 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.


AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) issued its quarterly earnings data on Monday, February, 24th. The medical equipment provider reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The medical equipment provider had revenue of $28.16 million for the quarter, compared to analysts' expectations of $28.10 million. AxoGen had a negative net margin of 27.30% and a negative return on equity of 19.32%. AxoGen's revenue was up 20.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS. View AxoGen's Earnings History.

When is AxoGen's next earnings date?

AxoGen is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for AxoGen.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $124-128 million, compared to the consensus revenue estimate of $131.75 million.

What price target have analysts set for AXGN?

5 Wall Street analysts have issued 1-year price objectives for AxoGen's stock. Their forecasts range from $21.00 to $28.00. On average, they expect AxoGen's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price. View Analyst Price Targets for AxoGen.

What is the consensus analysts' recommendation for AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

Has AxoGen been receiving favorable news coverage?

Media headlines about AXGN stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AxoGen earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for AxoGen.

Are investors shorting AxoGen?

AxoGen saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,660,000 shares, a decrease of 18.6% from the January 15th total of 2,040,000 shares. Based on an average daily volume of 355,000 shares, the days-to-cover ratio is presently 4.7 days. Currently, 4.7% of the shares of the stock are sold short. View AxoGen's Current Options Chain.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Advanced Micro Devices (AMD), Xilinx (XLNX), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Micron Technology (MU), Amarin (AMRN) and NVIDIA (NVDA).

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (15.15%), Baillie Gifford & Co. (2.61%), State Street Corp (2.55%), William Blair Investment Management LLC (2.34%), Bank of New York Mellon Corp (2.22%) and Bank of America Corp DE (2.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Renaissance Technologies LLC, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Penn Capital Management Co. Inc., Perkins Capital Management Inc. and BerganKDV Wealth Management LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

Which institutional investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Point72 Asset Management L.P., Bank of America Corp DE, Bank of Montreal Can, Jacobs Levy Equity Management Inc., Granite Investment Partners LLC and Baillie Gifford & Co.. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $12.12.

How big of a company is AxoGen?

AxoGen has a market capitalization of $478.38 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. View Additional Information About AxoGen.

What is AxoGen's official website?

The official website for AxoGen is http://www.axogeninc.com/.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  400 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  686
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel